ArticleEsophagus : official journal of the Japan Esophageal Society2026
Expression of cluster of differentiation 47 (CD47) and signal regulatory protein alpha (SIRPα) as prognostic biomarkers and potentially therapeutic targets in esophageal squamous cell carcinoma.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe cluster of differentiation 47 (CD47)-signal regulatory protein alpha (SIRPα) axis is a key regulator of innate immune surveillance, facilitating the neoplastic evasion of macrophage-mediated phagocytosis. Although this pathway has been implicated in tumor immune escape in multiple malignancies, its clinical and prognostic significance in esophageal squamous cell carcinoma (ESCC) remain to be fully elucidated.
methodsWe retrospectively analyzed 100 patients who underwent esophagectomy for resectable ESCC. Immunohistochemical testing determined SIRPα expression in peritumoral immune infiltrates and CD47 expression in tumor and immune cells, while tumor proportion score (TPS) and combined positive score (CPS) were used to evaluate CD47 staining. Survival outcomes and correlations with clinicopathological factors were also analyzed.
resultsIncreased expression of SIRPα, CD47 CPS, and CD47 TPS was detected in 47, 50, and 47% of patients, respectively. Elevated SIRPα expression was significantly associated with decreased overall survival. Also increased CD47 CPS and TPS was significantly associated with decreased overall survival and relapse-free survival. CD47 CPS was identified as an independent prognostic indicator for overall survival in multivariate Cox regression analysis (hazard ratio [HR] = 3.89; 95% confidence interval [CI] = 1.57-9.61; P = 0.003). Patients with concurrent high expression of both SIRPα and CD47 CPS demonstrated the poorest survival outcomes.
conclusionOverexpression of SIRPα and CD47, especially in tandem, is associated with poor clinical outcomes in ESCC, suggesting that the CD47-SIRPα axis may serve as a useful prognostic biomarker and a potential therapeutic target for newly immune checkpoint blockade in ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.